Question 1

What distinguishes a Phase 2/3 combined trial?

Accepted Answer

Phase 2/3 combined trials bridge efficacy assessment and large-scale comparative confirmation in a single expanding protocol. The Phase 2 portion identifies optimal dosing and collects early efficacy signals, while the Phase 3 portion expands enrollment and applies the primary statistical analysis to a larger population. This design reduces time from dose selection to pivotal evidence.

Question 2

How large are Phase 2/3 combined trials?

Accepted Answer

Phase 2/3 trials are larger than standalone Phase 2 studies but may be smaller than fully powered Phase 3 trials. Enrollment typically ranges from 200 to 1,000 participants, depending on the condition, endpoint, and statistical requirements. Interim analyses allow sample size adjustment if early results indicate more statistical power is needed.

Question 3

Who benefits most from Phase 2/3 trial designs?

Accepted Answer

Phase 2/3 designs particularly benefit patients with serious or rare conditions where standard treatments are inadequate. Because the Phase 2 and Phase 3 portions run as one continuous protocol, patients who enroll in Phase 2 may transition into the Phase 3 portion without interruption—a continuity of care advantage compared to sequential separate studies.

Phase 2 / Phase 3 Clinical Trials

Frequently Asked Questions — Phase 2 / Phase 3 Trials

Active Phase 2 / Phase 3 Studies